Opendata, web and dolomites

IMMUNOTRAP SIGNED

Diagnosis test for immuno-oncology therapies.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IMMUNOTRAP project word cloud

Explore the words cloud of the IMMUNOTRAP project. It provides you a very rough idea of what is the project "IMMUNOTRAP" about.

force    surface    pharmaceutical    until    inmuno    contact    solution    market    measured    ago    1980s    prize    platform    cancers    drugs    performance    exhibit    opportunity    interact    receptors    plasmon    marketing    efforts    assessing    laser    endpoint    samples    homogeneous    therapies    nobel    selecting    few    cells    tumors    start    back    cell    flow    entry    suitable    interaction    optical    innovation    breaking    techniques    impetux    clinical    immunoassays    invention    routes    drifting    act    father    oncology    confirm    disrupting    uses    tweezers    transferring    binding    2018    awarded    ground    light    screening    unmet    fundamental    cancer    efficient    mechanically    resonance    genetic    thanks    physical    forces    heterogeneity    precisely    generally    cytometry    characterization    mutations    immune    differently    create    company    diagnosis    affinity    patient    commercial    recognition    immunotherapies    treatments    adoptive    successful    technique    offers    industry    boost    intellectual    workhorse    physics    immunotrap    transfer    personalised   

Project "IMMUNOTRAP" data sheet

The following table provides information about the project.

Coordinator
IMPETUX OPTICS SL 

Organization address
address: CALLE TRIAS I GIRO 15
city: BARCELONA
postcode: 8034
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPETUX OPTICS SL ES (BARCELONA) coordinator 50˙000.00

Map

 Project objective

Cancers exhibit a large heterogeneity in terms of genetic mutations, so they respond differently to the same drugs. This is why oncology is rapidly drifting towards treatments with new disrupting personalised inmuno-oncology therapies based on adoptive T-cell transfer (ACT). These therapies aim at selecting the most efficient T cells against tumors and transferring them back to the patient. This kind of Immunoassays are generally carried out with endpoint measurements like Surface Plasmon Resonance or Flow Cytometry. However, these techniques do not allow assessing the binding process between the immune and the target cell, which represents a fundamental step of the recognition phase where large efforts against cancer focus. IMPETUX has developed a solution to address this unmet need. The characterization of this affinity will be achieved through the measurement of the interaction force between them with IMMUNOTRAP: a platform for cell screening based on IMPETUX‘s optical tweezers. This technology uses a highly-focused laser light to mechanically interact with the sample without physical contact. The recent 2018 Nobel Prize in Physics was awarded to the intellectual father of this technique for his ground-breaking invention in the 1980s. However, it was not until few years ago that forces could start being measured on non-homogeneous samples, such as cells, thanks to the technology developed by IMPETUX. The IMMUNOTRAP has the potential to become the workhorse in the screening of the best performance receptors for their use in immunotherapies and offers IMPETUX the opportunity to address a high-growth potential market: the pharmaceutical industry and clinical diagnosis. It represents, therefore, a key opportunity to boost the company’s growth. Thus, the objectives of the present innovation project is precisely to confirm the potential of the proposal to create value and to identify the most suitable marketing and commercial routes for a successful market entry.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOTRAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOTRAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More